Acorda Therapeutics Inc. (NASDAQ:ACOR) has been working on developing an inhalable drug treatment therapy, which is capable of treating Parkinson’s. This drug is called CVT-301, and according to the company, things are looking confident, for the usability of the drug.
The reason behind this confidence is due to the fact that the drug, recently just passed Phase III of its clinical trial period.
Details about the CVT-301 drug and its performance in the trials
Those who suffer from Parkinson’s disease, and took place in this clinical trial, allegedly, saw a vast improvement in their motor skills ability. This was made in comparison with a Placebo as a control substance.
This is not the only positive clinical trials that the CVT-301 has gone through. According to those well-versed in the matter, the Phase III trial just boasted a higher positive impact in patients, similar to that of the Phase 2B trials, ensuring the confidence behind the safety, and efficiency of the drug.
The trial itself consisted of three separate group tests. These were namely, 84 mg CVT-301, 60 mg CVT-301, as well as a placebo (a substance without therapeutic effects). The most significant result that this drug achieved, was the convincing win over the Placebo, in terms of treatment efficiency or Scale-Part 3 (UPDRS III) score. In the test, it was also made clear that the drug did exceptionally well, in terms of safety for the patients who inhaled the drug.
How does CVT-301 work in the treatment process
The drug itself is inhalable and is most likely to be distributed via a pulmonary inhalable medium, in order to ensure convenience, when administrating to patients. However, upon the evaluation of the drug, it was warned that with current oral implementations, the drug may be slow acting, due to taking a longer duration of time to reach the brain.
However, with the system that the company has developed, which it intends to release the drug, it is possible to eradicate the slow process, which allows for a timely treatment process.